Best clinical management of tenosynovial giant cell tumour (TGCT): A consensus paper from the community of experts
2022 · Cancer Treatment Reviews · 86 citations
https://doi.org/10.1016/j.ctrv.2022.102491
H
Herbert H. Loong
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
315
Papers
8.5K
Citations
41
h-index
100
i10-index
Herbert H. Loong is an academic researcher from Chinese University of Hong Kong. The author has contributed to research in topics: Lung Cancer Treatments and Mutations & Lung Cancer Research Studies & Cancer Genomics and Diagnostics. The author has an h-index of 41, co-authored 268 publications.
ORCID: 0000-0002-6607-1106Papers by this author
worksCeritinib plus Nivolumab in Patients with Advanced ALK-Rearranged Non–Small Cell Lung Cancer: Results of an Open-Label, Multicenter, Phase 1B Study
2019 · Journal of Thoracic Oncology · 76 citations
https://doi.org/10.1016/j.jtho.2019.10.006
Cost Effectiveness of PD-L1-Based Test-and-Treat Strategy with Pembrolizumab as the First-Line Treatment for Metastatic NSCLC in Hong Kong
2019 · PharmacoEconomics - Open · 41 citations
https://doi.org/10.1007/s41669-019-00178-7
Phase III Study of Selpercatinib Versus Chemotherapy ± pembrolizumab in Untreated <i>RET</i> Positive Non-Small-Cell Lung Cancer
2020 · Future Oncology · 37 citations
https://doi.org/10.2217/fon-2020-0935
Recommendations for the use of next-generation sequencing in patients with metastatic cancer in the Asia-Pacific region: a report from the APODDC working group
2023 · ESMO Open · 36 citations
https://doi.org/10.1016/j.esmoop.2023.101586
Profiles of lipids, blood pressure and weight changes among premenopausal Chinese breast cancer patients after adjuvant chemotherapy
2017 · BMC Women s Health · 33 citations
https://doi.org/10.1186/s12905-017-0409-8
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat